Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
Status:
Completed
Trial end date:
2020-03-03
Target enrollment:
Participant gender:
Summary
This phase I/IB trial studies the side effects and best dose of eribulin mesylate and
everolimus in treating patients with breast cancer that does not have estrogen receptors,
progesterone receptors, or large amounts of human epidermal growth factor receptor 2 protein
(triple-negative) and has spread to other places in the body (metastatic). Eribulin mesylate
and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth.